Clinical trials
Observational Bipolar Disorder trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 14 |
| Recruiting | 6 |
| Completed | 5 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shanghai Mental Health Center | 7 |
| Central South University | 4 |
| Peking University | 4 |
| Tianjin Anding Hospital | 2 |
| AstraZeneca | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Islamic Azad University, Sanandaj | 1 |
| Jiangsu Province Nanjing Brain Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bipolar Disorder | 26 |
| Major Depressive Disorder | 8 |
| Schizophrenia | 6 |
| Mental Disorders | 3 |
| Anxiety Disorders | 2 |
| Autism Spectrum Disorder | 2 |
| Cognitive Dysfunction | 2 |
| Mood Disorders | 2 |
| Alzheimer Disease | 1 |
| Conduct Disorder | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.